Last reviewed · How we verify
GEMCITABINE CISPLATINE
Gemcitabine and cisplatin work synergistically as a chemotherapy combination, with gemcitabine inhibiting ribonucleotide reductase to disrupt DNA synthesis and cisplatin forming DNA crosslinks to prevent replication.
Gemcitabine and cisplatin work synergistically as a chemotherapy combination, with gemcitabine inhibiting ribonucleotide reductase to disrupt DNA synthesis and cisplatin forming DNA crosslinks to prevent replication. Used for Advanced or metastatic non-small cell lung cancer, Urothelial carcinoma, Ovarian cancer.
At a glance
| Generic name | GEMCITABINE CISPLATINE |
|---|---|
| Sponsor | University Hospital, Rouen |
| Drug class | Chemotherapy combination (nucleoside analog + platinum alkylating agent) |
| Target | DNA synthesis machinery; DNA structure |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that interferes with DNA synthesis by inhibiting ribonucleotide reductase and being incorporated into DNA, causing chain termination. Cisplatin is a platinum-based alkylating agent that forms covalent DNA adducts and crosslinks, preventing DNA unwinding and replication. Together, they provide complementary cytotoxic mechanisms targeting rapidly dividing cancer cells.
Approved indications
- Advanced or metastatic non-small cell lung cancer
- Urothelial carcinoma
- Ovarian cancer
- Pancreatic cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia)
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Anemia
- Alopecia
Key clinical trials
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer (PHASE3)
- PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma (PHASE2)
- Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer (PHASE3)
- Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients (PHASE2)
- First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients (PHASE2)
- Endostar First-line Treatment of Advanced NSCLC (PHASE2)
- Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GEMCITABINE CISPLATINE CI brief — competitive landscape report
- GEMCITABINE CISPLATINE updates RSS · CI watch RSS
- University Hospital, Rouen portfolio CI